Evergreen Therapeutics, Inc. Worked with Leading Laboratories in the United States in Conducting Animal Experiments that Demonstrate the Effectiveness of PR2005 in Treating Cytokine Storms Caused by COVID-19-Evergreen Therapeutics, Inc.

Evergreen Therapeutics, Inc. Worked with Leading Laboratories in the United States in Conducting Animal Experiments that Demonstrate the Effectiveness of PR2005 in Treating Cytokine Storms Caused by COVID-19

Source：Egpharm Date: Jun,2020 Views: 1021

In July 2020, Shenzhen Evergreen Therapeutics Co., Ltd. announced its partnership with a leading U.S. laboratory to conduct animal experiment on the effectiveness of PR2005 in treating cytokine storms caused by COVID-19. This trial will provide further evidence of the effectiveness of PR2005 in the treatment of COVID-19.

截图-20210907133530

The laboratory is an independent, non-profit biomedical research institution dedicated to contributing to better health care in the future. Based on each person's unique genetic makeup, the laboratory will discover accurate disease genome solutions, and entrust the global biomedical community with a common mission – to improve human health. The laboratory is a cancer center designated by the National Cancer Institute that hosts the NIH research center on aging and systemic genetics. It is also the source of more than 8,000 gene-defined mouse lines around the world, home to the Mouse Genome Informatics database, and an international center for science courses, conferences, training, and education.

Evergreen Therapeutics Inc.'s COVID-19 Oral Drug EG-009 was Officially Approved by the FDA to Enter Phase I Clinical Trial Evergreen Therapeutics, Inc. Announced to Develop EG-009 for the Treatment of Moderate to Severe COVID-19